Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSKIRA-3: Fostamatinib in RA with Inadequate Response to TNF-alpha Antagonist
NCT01197755Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of fostamatinib in rheumatoid arthritis (RA), sponsored by AstraZeneca. Started Sep 2010; status: completed.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01197755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197755.